Pathological scarring, particularly keloid formation, represents a major therapeutic hurdle in modern dermatological and surgical practice. Keloids extend far beyond original wound margins, causing severe cosmetic deformity, pain, and physical restriction. Although clinician researchers have investigated fibroproliferative disorders for decades, the precise molecular mechanics that perpetuate keloid progression remain incompletely understood. However, groundbreaking transcriptomic profiling has recently elucidated a crucial driver of disease activity. The amphiregulin (AREG) and epidermal growth factor receptor (EGFR) signaling network directly accelerates fibroblast hyperactivity, establishing a promising target for novel pharmacological interventions.

Unraveling the Pathogenesis of Keloid Progression

Understanding how dermal scars escape normal regulatory checks requires precise molecular dissecting. Researchers systematically evaluated global gene expression profiles by performing transcriptomic profiling of keloid fibroblasts alongside matched normal skin fibroblasts. Consequently, this high-resolution comparative analysis identified a prominent upregulation of amphiregulin within keloid tissue samples. Amphiregulin functions as a key transmembrane ligand belonging to the epidermal growth factor family.

Furthermore, investigators noted that amphiregulin expression directly correlates with clinical disease severity in patients. Higher levels of this signaling molecule correspond to larger, more aggressive scar tissue formations. In vitro functional assays further confirmed these transcriptomic observations. When exposed to recombinant amphiregulin, isolated keloid fibroblasts exhibited dramatic increases in cellular proliferation, accelerated migratory behavior, and heightened extracellular matrix production.

Thus, amphiregulin does not act merely as a passive bystander in tissue repair. Instead, it acts as an active driver of abnormal wound healing. By stimulating fibroblast expansion and excessive extracellular matrix deposition, high amphiregulin concentrations convert standard physiological repair into persistent, invasive tissue expansion. These pivotal findings redefine how clinicians conceptualize the ongoing inflammatory and fibrotic cascades that characterize stubborn keloid lesions.

The Dual Mechanism of Amphiregulin and EGFR Activation

To determine how amphiregulin executes its pro-fibrotic signaling, scientists investigated its direct interaction with cell surface receptors on dermal fibroblasts. Their mechanistic studies confirmed that amphiregulin signalling mediates keloid fibroblast activation specifically through the epidermal growth factor receptor. When amphiregulin binds to EGFR, it initiates receptor dimerization and intracellular phosphorylation events that convert quiescent resting cells into hyperactive repair elements.

Moreover, this binding creates a continuous feedback loop within the local scar microenvironment. Activated keloid fibroblasts produce elevated levels of extracellular matrix proteins, including type I and type III collagen, fibronectin, and glycosaminoglycans. In normal dermal repair, growth factor signaling subsides rapidly once re-epithelialization completes. Conversely, keloid tissue maintains persistent receptor stimulation, causing fibroblasts to resist normal physiological apoptosis.

Additionally, this sustained receptor engagement promotes continuous tissue remodeling, driving the characteristic expansion beyond the original injury boundaries. By identifying EGFR as the mandatory obligate partner for amphiregulin signaling, researchers have established a clear molecular target. Disruption of this receptor interaction could effectively halt the persistent fibrotic stimulus. Consequently, blocking EGFR signaling represents a highly logical strategy to prevent runaway matrix production in susceptible patient populations.

Downstream Signaling: The MAPK Pathway in Fibroblast Activation

To fully understand how membrane receptor binding triggers intracellular matrix synthesis, researchers explored downstream enzymatic cascades. The investigation revealed that the mitogen-activated protein kinase signaling pathway functions as a key downstream effector of the AREG-EGFR axis. Upon EGFR activation, signal transduction rapidly triggers a phosphorylation cascade through extracellular signal-regulated kinases within the cytosol.

Specifically, activation of the MAPK pathway regulates crucial nuclear transcription factors that drive gene expression for cell cycle progression and matrix protein production. Consequently, keloid fibroblasts maintain an abnormally high rate of cell division while simultaneously secreting excessive structural proteins. Furthermore, the elevated MAPK activity enhances cellular motility, enabling keloid fibroblasts to invade adjacent uninjured cutaneous tissues.

In contrast, suppressing MAPK signal transduction significantly reduces the synthetic capacity and migratory drive of keloid-derived cells. However, direct systemic inhibition of generalized intracellular kinase cascades often carries substantial cytotoxicity risks. Therefore, targeting the upstream cell-surface initiation point—specifically the AREG-EGFR receptor complex—offers a far more precise and clinically tolerable therapeutic approach. This mechanistic insight bridges the gap between basic receptor biology and targeted pharmacological interventions for severe cutaneous fibrosis.

Translational Potential of Gefitinib in Keloid Progression

Given the critical involvement of EGFR signal transduction, attention turned to existing small-molecule receptor antagonists. Gefitinib, a potent and selective epidermal growth factor receptor tyrosine kinase inhibitor, emerged as a promising drug candidate for interrupting this pathological axis. While clinicians currently prescribe gefitinib primarily for non-small cell lung cancer, its well-established pharmacology makes it an ideal candidate for drug repurposing in dermatology.

Investigators tested whether gefitinib could effectively interrupt the pathological signaling driving keloid progression. In laboratory models, administration of gefitinib successfully blocked amphiregulin-induced receptor phosphorylation. Consequently, downstream MAPK pathway activation decreased dramatically, returning cellular behavior toward normal physiological baselines. Keloid fibroblasts treated with gefitinib showed marked reductions in cellular proliferation rates and migration distances.

Furthermore, gefitinib treatment directly downregulated the expression of major extracellular matrix genes, including collagen types I and III. By selectively competing with adenosine triphosphate at the intracellular catalytic domain of EGFR, gefitinib neutralizes the pro-fibrotic signals delivered by elevated amphiregulin levels. Therefore, these preclinical findings strongly validate receptor tyrosine kinase inhibition as a viable strategy to manage aggressive scar expansion.

Preclinical Evidence from Explants and Animal Models

To validate these molecular insights in physiologically relevant settings, researchers evaluated gefitinib across advanced ex vivo and in vivo translational models. First, investigators utilized human keloid skin explants, which preserve the complex three-dimensional architecture and native cellular cross-talk of human scar tissue. Treatment of these human explants with gefitinib resulted in a profound reduction of extracellular matrix component deposition and histological tissue density.

Second, researchers established a robust keloid-bearing nude mouse xenograft model to evaluate therapeutic efficacy in a living organism. When human keloid tissues transplanted into these immunocompromised mice received gefitinib, the treatment suppressed further scar growth and significantly decreased internal collagen accumulation. Notably, the treated xenografts demonstrated reduced fibroblast cellularity and normalized matrix organization without causing systemic toxicity.

Additionally, quantitative histopathological evaluations confirmed that gefitinib treatment markedly lowered collagen density and reduced phosphorylated EGFR expression within the tissue grafts. These compelling results demonstrate that target inhibition translates directly into tangible structural improvements in complex living tissues. Consequently, these preclinical findings provide robust proof-of-concept evidence supporting the clinical translation of EGFR inhibitors into human scar management strategies.

Clinical Implications for Future Dermatological Interventions

The discovery of the AREG-EGFR-MAPK signaling pathway marks a significant milestone in scar management research. For decades, dermatologists and plastic surgeons relied primarily on intralesional corticosteroids, cryotherapy, or surgical excision. However, these traditional interventions often yield unpredictable clinical results and high recurrence rates. The identification of targetable molecular drivers allows clinicians to envision highly specific biological therapies.

Furthermore, the translational relevance of gefitinib opens exciting possibilities for topical or local intralesional delivery formulations. Direct local application could deliver therapeutic drug concentrations directly into keloid tissue while completely avoiding systemic side effects. Moreover, combining EGFR inhibitors with existing modalities, such as laser therapy or surgical excision, might prevent postoperative scar recurrence in high-risk patients.

Ultimately, these findings lay the foundation for targeted molecular therapies in reconstructive surgery and dermatology. As clinical trials evaluate local delivery systems, medical practice moves closer to personalized, mechanism-based care for severe scar disorders.

Frequently Asked Questions

What is amphiregulin and how does it contribute to keloid formation?

Amphiregulin is a transmembrane ligand belonging to the epidermal growth factor family. In keloid tissue, amphiregulin expression is significantly upregulated and correlates directly with disease severity. When binding to epidermal growth factor receptors on keloid fibroblasts, amphiregulin triggers hyperproliferation, accelerated cell migration, and excessive collagen production. This continuous signaling prevents normal scar resolution, driving excessive tissue accumulation and characteristic lesion expansion beyond original injury boundaries.

How does gefitinib halt the molecular processes of keloid progression?

Gefitinib acts as a selective inhibitor of the epidermal growth factor receptor. By binding to the intracellular domain of EGFR, gefitinib blocks amphiregulin-induced receptor phosphorylation. This blockade prevents the downstream activation of the MAPK signaling cascade within keloid fibroblasts. Consequently, gefitinib dramatically suppresses cellular proliferation, halts fibroblast migration, and significantly reduces the synthesis and deposition of dense extracellular matrix proteins in scar tissue.

Could gefitinib become a routine clinical treatment for keloid scars?

While gefitinib shows compelling efficacy in human skin explants and animal models, further clinical trials are necessary before routine clinical adoption. Systemic oral administration of gefitinib causes cutaneous toxicities; therefore, researchers are currently exploring localized delivery methods, such as topical formulations or intralesional micro-injections. These targeted delivery approaches aim to achieve high therapeutic drug levels within the scar while minimizing systemic side effects in patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Dong E et al. The Amphiregulin-EGFR Axis Drives Fibroblast Activation to Promote Keloid Progression. Br J Dermatol. 2026 Jul 23. doi: undefined. PMID: 42487137.


2. Inui S, Itami S. Molecular mechanisms of keloid and hypertrophic scar formation. J Dermatol Sci. 2012;66(1):16-20.


3. Wang Z, et al. EGFR signaling in skin fibrosis and tissue remodeling. Fibrogenesis Tissue Repair. 2020;13(2):45-53.